NEW YORK (GenomeWeb) – Biotech firm Evogen is moving from its traditional focus on infectious disease threat detection to precision medicine and molecular diagnostics, with a primary emphasis on neurology.
The company's first product in this area is the EvoScore START test, a blood-based proteomic assay intended to help doctors distinguish epileptic seizures from seizures with other causes. According to Todd Wallach, Evogen's president and CEO, the company plans to launch the diagnostic in targeted markets as a laboratory-developed test in 2017.